Lincoln, Nebraska, Oct. 24, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ/:NRC) today announced that it will provide an online web simulcast of its 2023 third quarter earnings conference call on Wednesday, November 8, 2023. The Company’s results for the 2023 third quarter will be released after the close of the market on Tuesday, November 7, 2023.
The live broadcast of National Research Corporation’s conference call will begin at 11:00 a.m. Eastern Time on November 8, 2023. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
A live audio webcast can be accessed at https://events.q4inc.com/attendee/533804877. The webcast will also be available for replay.
For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it., or visit www.nrchealth.com.
Last Trade: | US$14.69 |
Daily Change: | 0.04 0.27 |
Daily Volume: | 79,275 |
Market Cap: | US$338.750M |
July 28, 2025 April 28, 2025 February 25, 2025 January 27, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load